These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 34220335)
21. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study. Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926 [TBL] [Abstract][Full Text] [Related]
22. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study. Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374 [TBL] [Abstract][Full Text] [Related]
23. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy. Hou J; Tang Y; Chen Y; Chen D Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341 [TBL] [Abstract][Full Text] [Related]
24. Thyroid volume and severity of Graves' orbitopathy. Profilo MA; Sisti E; Marcocci C; Vitti P; Pinchera A; Nardi M; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Rago T; Marinò M Thyroid; 2013 Jan; 23(1):97-102. PubMed ID: 23088654 [TBL] [Abstract][Full Text] [Related]
25. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy. Woo YJ; Jang SY; Lim TH; Yoon JS Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504 [TBL] [Abstract][Full Text] [Related]
26. Serum thyroglobulin is associated with orbitopathy in Graves' disease. Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213 [TBL] [Abstract][Full Text] [Related]
27. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy. He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501 [TBL] [Abstract][Full Text] [Related]
30. Changes in Serum Immunoglobulin G4 Levels in Patients with Newly Diagnosed Graves' Disease. Hiratsuka I; Yamada H; Itoh M; Shibata M; Takayanagi T; Makino M; Sugimura Y; Hayakawa N; Hashimoto S; Suzuki A Exp Clin Endocrinol Diabetes; 2020 Feb; 128(2):119-124. PubMed ID: 30235492 [TBL] [Abstract][Full Text] [Related]
31. miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients. Craps J; Joris V; Baldeschi L; Daumerie C; Camboni A; Buemi A; Lengelé B; Behets C; Boschi A; Mourad M; Many MC; Dessy C Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008579 [TBL] [Abstract][Full Text] [Related]
32. Graves' Disease Patients with Persistent Hyperthyroidism and Diffuse Lymphoplasmacytic Infiltration in the Thyroid Show No Histopathological Compatibility with IgG4-Related Disease. Nishihara E; Hirokawa M; Ito M; Fukata S; Nakamura H; Amino N; Miyauchi A PLoS One; 2015; 10(7):e0134143. PubMed ID: 26218874 [TBL] [Abstract][Full Text] [Related]
33. Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians. Bayarmunkh O; Ganbold C; Das S; Davaatseren U; Minjuurdorj NE; Jav S PLoS One; 2022; 17(11):e0277055. PubMed ID: 36395261 [TBL] [Abstract][Full Text] [Related]
34. Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves' orbitopathy. Pawlowski P; Poplawska I; Mysliwiec J; Dik WA; Eckstein A; Berchner-Pfannschmidt U; Milewski R; Lawicki S; Dzieciol-Anikiej Z; Rejdak R; Reszec J Folia Histochem Cytobiol; 2020; 58(1):37-45. PubMed ID: 32176314 [TBL] [Abstract][Full Text] [Related]
35. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor. Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525 [TBL] [Abstract][Full Text] [Related]
36. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy. Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970 [TBL] [Abstract][Full Text] [Related]
37. Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy. Lanzolla G; Puccinelli L; Giudetti M; Comi S; Menconi F; Maglionico MN; Posarelli C; Figus M; Marcocci C; Marinò M J Endocrinol Invest; 2023 Feb; 46(2):337-344. PubMed ID: 36030301 [TBL] [Abstract][Full Text] [Related]
38. Peripheral blood mononuclear cells - Can they provide a clue to the pathogenesis of Graves' Orbitopathy? Basak M; Sanyal T; Kar A; Bhattacharjee P; Das M; Chowdhury S Endocrine; 2022 Feb; 75(2):447-455. PubMed ID: 34545512 [TBL] [Abstract][Full Text] [Related]